06/11/2014 - 11:58am

More than 29 million people in the United States have diabetes, up from the previous estimate of 26 million in 2010, according to a report released Tuesday by the Centers for Disease Control and Prevention.

05/23/2014 - 11:42am

Omnis Health recently announced the launch of EmbraceEVO, a new blood-glucose meter.

05/19/2014 - 1:06pm

New research published in Diabetologia, the journal of the European Association for the Study of Diabetes, found that brief bursts of intense exercise before meals — termed exercise "snacking" by the study authors — helps control blood sugar in people with insulin resistance more effectively than one daily 30-minute session of moderate exercise.

05/16/2014 - 9:51am

A multi-year medical research study released Thursday that examined health issues among U.S. Hispanic/Latino groups has yielded data indicating that less than half of the participants diagnosed with diabetes had the condition under control.

05/06/2014 - 9:25am

In a study released Saturday that included data from more than 3 million children and adolescents from diverse geographic regions of the United States, researchers found that the prevalence of both Type 1 and Type 2 diabetes increased significantly between 2001 and 2009.

04/16/2014 - 1:11pm

Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge.

04/15/2014 - 10:45am

The Food and Drug Administration on Tuesday announced that it approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.

04/09/2014 - 9:47am

Omnis Health on Tuesday announced the launch of EmbracePro, a blood-glucose meter for medical professionals.

04/03/2014 - 7:55am

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.